The combination of chemotherapy with anti-epidermal growth factor receptor antibodies such as cetuximab and panitumumab which prolong the survival time in the past few years have been widely adopted for the treatment of metastatic colorectal cancer.However,a large number of patients develop resistance to these agents,while there is no standard treatment after acquired resistance yet.Therefore,finding out the mechanisms of acquired drug resistance and putting forward reasonable methods to overcome the acquired resistance will be improve its curative effect.

ObjectiveTo investigate the method of osteo-periosteal turned over orthotopically for treating chondromalacia patellae disease and observe the mid-long term efficacy postoperatively.Methods From April 1996 to June 2000,21 patients with chondromalacia patellae were treated in our hospital.Amone them,13 cases were performed osteo-periosteal turned over orthotopically,including 3 males,10 females; with the mean age of 59 years(range,47-65 years).HSS and Lysholm knee rating scale were employed to analysis the results.ResultsThe patients were followed up from 114 to 162 months(mean,133.2 months).One of the patients lost follow-up due to death.Before operation the HSS knee score was 20-58 (34.2±3.8),and 1 year,3 year,5 year,7 year,and 9 year after operation the HSS knee score were 55-70(60.0±7.0),55-82 (64.1±5.9),60-90 (70.1±3.2),50-85 (63.1±4.1),and 50-75 (57.3±2.9) respectively.And Lysholm knee rating scale also showed similar results.The chondromalacia patellae patients before and after operation were significant different.Bone periosteum transplant tissue and surrounding defective tissue healed perfectly,functions recovered perfectly.ConclusionThe method of osteo-periosteal turned over orthotopically has the capabilities to form cartilage.The therapeutic effect and facies articularis patellar is satisfactory.But it only can restore articular cartilage of patellar and does not help for genual malformation.

BACKGROUNDTo evaluate the results of combined chemotherapy with paclitaxel (PTX, taxol) plus cisplatin (DDP) in the treatment of advanced non small cell lung cancer (NSCLC).

METHODSFrom January 1997 to December 2002, forty-seven patients with advanced non-small cell lung cancer received PTX 135-180 mg/m² by intravenous infusion, on day 1, and DDP 40 mg/time by intravenous infusion,on days 1-3. The treatment was repeated every 3 weeks, up to 2 or 3 cycles.

RESULTSForty-six patients were evaluable for efficacy. One patient got complete response (2.2%), and 16 got partial response (34.8%), with an overall response rate of 37.0%. The main toxicities were myelosuppression, nausea and vomiting, and other side effects were mild.

CONCLUSIONSA high response rate can be obtained in advanced NSCLC by PTX plus DDP. PTX is a promising antitumor agent with tolerable toxicity.

Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. The systemic antitumor therapy of advanced NSCLC has undergone renovations of chemotherapy, targeted therapy and immunotherapy, which results in greatly improved survival for patients with advanced NSCLC. Immune checkpoint inhibitors (ICIs), especially targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1), has changed the treatment paradigm of NSCLC. ICIs have become the standard treatment for advanced NSCLC without epidermal growth factor receptor(EGFR) mutation or anaplastic lymphomakinase(ALK) translocation in the first- or second-line setting, and for locally advanced NSCLC following concurrent radiotherapy and chemotherapy. ICIs are also promising in adjuvant/neoadjuvant therapy. More and more ICIs have been approved domestically for the treatment of NSCLC. Led by the NSCLC expert committee of Chinese Society of Clinical Oncology (CSCO), this consensus was developed and updated based on thoroughly reviewing domestic and foreign literatures, clinical trial data, systematic reviews, experts' discussion and the consensus(2019 version). This consensus will aid domestic clinicians in the treatment of NSCLC with ICIs.
.